Going direct: notes on Eli Lilly at a trillion | Alex’s blog

Personal site for posts about my interests: the biotech industry, medicine, molecular biology, neuroscience, biorisk, science, consciousness, AI, innovation, decision making, philosophy, games, sci-fi, probability, and forecasting (among other things). I write to learn, mostly about biotech.

A few weeks ago, Eli Lilly CEO Dave Ricks appeared on Stripe’s “Cheeky Pint” podcast . It’s rare 1 for pharma executives to make unscripted media appearances (the industry is risk averse by nature), so seeing one sit down with the Collison brothers — on a tech podcast, no less — is notable. Pharma’s deliberate distance 2 has come at a cost: the industry has mostly failed to establish positive relationships with consumers. Tech, by contrast, consistently ranks as one of the most liked industries; pharma is one of the most disliked . Tech CEOs are household names, yet hardly anyone outside the i

related reading

• Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharmacheekypint.substack.com
• The Ozempocalypse Is Nigh - by Scott Alexanderastralcodexten.com
• Stratechery by Ben Thompson – On the business, strategy, and impact of technology.stratechery.com
• Articles — Asimov Presspress.asimov.com
• Laws of Tech: Commoditize Your Complement · Gwern.netgwern.net
• Beyond Steel Tanksasimov.press
• Corporate Ozempic. If you want to understand how AI is… | by Scott Galloway | Mediummedium.com
• Going Founder Mode On Cancer - by Elliot Hershbergcenturyofbio.com
• Why Does Ozempic Cure All Diseases?astralcodexten.com
• Pharma Virumque | Slate Star Codexslatestarcodex.com
• Some questions about biotech that I find interesting | Alex’s blogatelfo.github.io
• For Life and Money: How to Make Money by Making Life Longer and Betterforever.ai